A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 14 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 14 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2016.
- 04 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.